Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Impurities & degradation products

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present.

704 FDA drug recalls with this cause, newest first.

Every drug has a specification for how much of each impurity or breakdown product it may contain. These recalls are lots that exceeded one of those limits - often a related compound formed during manufacturing or storage, or an out-of-specification result found during routine stability testing. Nitrosamine impurities are common enough to get their own category; everything else lands here.

Class II · Moderate risk

Ciclopirox Shampoo

Failed Impurity/Degradation specifications: OOS results obtained at the 18-month timepoint

Ongoing Impurity / degradation Sun Pharma /Taro NDC 51672-1351-08 D-0240-2026
Class III · Low risk

Clindamycin Phosphate USP

Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.

Ongoing Impurity / degradation Sun Pharmaceutical Industries INC NDC 51672-4081-4 D-0257-2026
Class II · Moderate risk

Ganirelix Acetate Injection

Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.

Ongoing Impurity / degradation Lupin Pharmaceuticals Inc. NDC 70748-274-01 D-0220-2026
Class II · Moderate risk

Bromocriptine Mesylate Capsules

Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules.

Ongoing Impurity / degradation Zydus Pharmaceuticals (USA) Inc NDC 68382-110-06 D-0159-2026
Class III · Low risk

Fesoterodine Fumarate

Failed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.

Ongoing Impurity / degradation Alembic Pharmaceuticals Limited NDC 62332-175-30 D-0156-2026
Class III · Low risk

Everolimus tablets 5mg

Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.

Ongoing Impurity / degradation Endo USA, Inc. NDC 49884-125-91 D-0139-2026
Class II · Moderate risk

Gabapentin Capsules

Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

Ongoing Impurity / degradation The Harvard Drug Group LLC NDC 0904-6665-61 D-0031-2026
Class II · Moderate risk

Gabapentin Capsules

Failed Impurities/Degradation Specifications: an out of specification result obtained during routine stability testing for Highest Unknown Impurity .

Ongoing Impurity / degradation The Harvard Drug Group LLC NDC 0904-6665-61 D-0030-2026
Class II · Moderate risk

Entecavir Tablets

Failed impurity/degradation specifications:Out of Specification result for an individual organic impurity

Ongoing Impurity / degradation Zydus Pharmaceuticals (USA) Inc NDC 68382-921-06 D-0002-2026
Class II · Moderate risk

Entecavir Tablets

Failed impurity/degradation specifications:Out of Specification result for an individual organic impurity

Ongoing Impurity / degradation Zydus Pharmaceuticals (USA) Inc NDC 68382-920-06 D-0001-2026
Class II · Moderate risk

Viorele

Failed Impurities/Degradation Specifications

Ongoing Impurity / degradation Glenmark Pharmaceuticals Inc., USA NDC 68462-318-29 D-0021-2026
Class II · Moderate risk

Succinylcholine Chloride Injection

Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity.

Ongoing Impurity / degradation Zydus Pharmaceuticals (USA) Inc NDC 70710-1377-1 D-0623-2025